1. Home
  2. ETON vs MAIA Comparison

ETON vs MAIA Comparison

Compare ETON & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

N/A

Current Price

$57.07

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.40

Market Cap

79.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ETON
MAIA
Founded
2017
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
79.0M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
ETON
MAIA
Price
$57.07
$1.40
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$39.33
N/A
AVG Volume (30 Days)
428.6K
443.8K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
0.41
N/A
Revenue
$79,950,000.00
N/A
Revenue This Year
$40.90
N/A
Revenue Next Year
$47.23
N/A
P/E Ratio
$136.12
N/A
Revenue Growth
104.94
N/A
52 Week Low
$14.27
$0.87
52 Week High
$66.37
$3.19

Technical Indicators

Market Signals
Indicator
ETON
MAIA
Relative Strength Index (RSI) 49.17 59.41
Support Level $15.75 $1.36
Resistance Level $66.37 $1.48
Average True Range (ATR) 2.54 0.06
MACD -1.32 0.01
Stochastic Oscillator 18.40 89.47

Price Performance

Historical Comparison
ETON
MAIA

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: